Additional Resources
These materials provide additional background on the problem of cancer drug overdosing, and highlight OCCA’s ongoing work in this space.
Government Action:
Videos:
- First International Summit on Interventional Pharmacoeconomics (2020)
- ASCO Recap (2021) – Video Excerpt
News Coverage, Op-Eds, and Blog Posts
- FDA commissioner, two senators raise concerns about patent abuse (2021)
- RIP MTD (Maximum Tolerated Dose): FDA to require sponsors to determine optimal dosage (2021)
- Optimize the dose: An optimal step forward for FDA (2021)
- FDA’s ‘Project Optimus’ Will Encourage Move Away From Conventional Dose-Finding (2021)
- Empowering the FDA to Require Dose Optimization (2021)
- Study identifies targeted therapy’s cardiac risks (2019)
- Funding Interventional Pharmacoeconomic Studies: A New Paradigm (2019)
- The Potential of Value-Based Prescribing in Oncology (2019)
- Archived News Coverage Op-Eds
Medical and Scientific Journal Articles
- Combination therapy patents: a new front in evergreening (2021)
- Dose Optimization of Pembrolizumab: Less May Be More (2021)
- Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message? (2021)
- A Pharmacokinetic Simulation Analysis of Less Frequent Dosing: Pharmacoeconomic Rationale for Dose De-Escalation (2021)
- Negative Innovation: When Patents are Bad For Patients (2021)
- Near- Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments (2021)
- The Abiraterone Dosing Chess Match (2021)
- Archived Journal Articles